Dr. Vijay V. Yeldandi

Dr. Vijay V. Yeldandi
Internal Medicine Specialist, Hyderabad

MD, FACP, FCCP

  • 1 Hospital
  • Dr. Vijay V. Yeldandi is consultant at Continental Hospitals, Hyderabad

Experience

Consultant, Continental Hospitals, Hyderabad

Specialities

  • Internal Medicine

Expertise

Education

MBBS, 1980, Osmania Medical College & Gandhi Medical College, Hyderabad

Fellow in Infectious Disease, 1988, Loyola University Medical Center, Chicago, USA

Diplomate in Infectious Disease, 1988, American Board of Internal Medicine, USA

Diplomate in Internal Medicine, 1986, American Board of Internal Medicine, USA

Practice Information

Continental Hospitals, Hyderabad

Continental Hospitals, Hyderabad

Plot No.3, Road no.2, IT & Financial Dist, Nanakramguda, Gachibowli, Hyderabad, Telangana - 500035

Patient Experience

Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Vijay V. Yeldandi and his staff know how they are doing and how they can improve their services.

Achievements & Contributions

  • Principal Investigator Phase I. Study of the safety and pharmacokinetics of AmBisome® (liposomal amphotericin-B) in adults receiving Anti-Neoplastic therapy or Bone Marrow Transplantation, 1994
  • Principal Investigator Phase II/III. A Randomized double-blind comparative trial of AmBisome® (liposomal Amphotericin B) vs. Amphotericin B in the empiric treatment of the febrile neutropenic patient, 1995
  • Principal Investigator. Human cytomegalovirus disease in lung transplant recipients. A study of the epidemiology and pathogenicity of human cytomegalovirus strains causing interstitial pneumonia in lung transplant recipients. In collaboration with Nell S. Lurain, Ph.D. Rush Pres St Lukes Medical Center
  • Principal Investigator. AmBisome® Open Label Trial
  • Co-Investigator. A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole vs. AmBisome® for Empirical Antifungal Therapy in Immunocompromised Patients with Persistent Fever and Neutropenia. Protocol Number: 150-603. (Pfizer and MSG). Member: NIAID Mycoses Study Group 1996-1999
  • Co-Investigator. A Multi-Center, Double Blind, Randomized, Crossover, Two Different Single Oral Doses Study to Compare The Pharmacokinetics, Safety and Tolerability of SDZ RAD in Stable Lung and Heart Lung Transplant Recipients With Pancreatic Insufficient Cystic Fibrosis and Without Cystic Fibrosis. (Novartis)
  • Co-Investigator. A one year randomized, multi-center, open label, parallel group study of the efficacy and safety of SDZ RAD tablets versus antilymphocyte globulin and azathioprine in lung or heart lung transplant recipients with bronchiolitis obliterans syndrome. (Novartis)
  • Principal Investigator. Early Detection of CMV Disease by The Hybrid Capture Assay. Loyola University Medical Center
  • Design and execution of Abbott Laboratories Phase I Study, Protocol # W00-359. Relative Bioavailability of Two Clarithromycin Formulations in Fasting Subjects. 2000-01
  • Design and execution of Abbott Laboratories Epidemiological Study, Protocol # W00-343. Microbiological Evaluation of Community Acquired Pneumococcal Pneumonia. 2000-01
  • Design and execution of Abbott Laboratories Phase III Study, Protocol # W00-348. Comparison of the Safety and Efficacy of Clarithromycin XL versus Penicillin V for the Treatment of Streptococcal Pharyngitis/Tonsillitis. 2000-01
  • Design and execution of Abbott Laboratories Phase III Study, Protocol # W00-349. Comparison of the Safety and Efficacy of Two formulations of Clarithromycin for the Treatment of Acute Exacerbation of Chronic Bronchitis. 2000-01
  • Design of Abbott Laboratories Protocol # M01-354. A Phase 2 Comparative Study of the Safety and Efficacy of Three Oral Doses of ABT-492 for the Treatment of Acute Bacterial Sinusitis
  • Principal Investigator. The ASSURE Trial: Theravance Protocol # I6424-203a: A phase 2, Randomized, Double Blind, Parallel-Group, Multinational Trial of Intravenous ARBELICTM (TD-6424) for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia
  • Principal Investigator. The FAST Trial: Theravance Protocol # I6424-202a: A phase 2, Randomized, Double Blind, Parallel-Group, Multinational Trial of Intravenous ARBELICTM (TD-6424) for the Treatment of Complicated Gram-Positive Skin and Skin Structure Infections
  • Principal Investigator. Fujisawa Protocol #FG-463-21-08: A Multicentre, Double Blind, Comparative, Randomised Study to Evaluate the Efficacy and Safety of Micafungin (FK463) versus Liposomal Amphotericin B (AmBisome®) in the Treatment of Invasive Candidiasis and Candidaemia
  • Principal Administrator and awardee. “Strengthening Management Support Services for HHS Global AIDS Program in the Republic of India” United States Centers for Disease Control and Prevention Cooperative agreement # U62/CCU025164-01-1. 2005 –2010
  • Principal Administrator and awardee. “Strengthening Non Governmental Organizations (NGOs) and Private-Sector Care Networks the Republic of India” United States Centers for Disease Control and Prevention Cooperative agreement # U62/CCU025160-02. 2005 –2010
  • Principal Administrator and awardee. “Technical assistance to the National AIDS Control Organization (NACO) of India” United States Centers for Disease Control and Prevention Cooperative agreement # 1U2GPS002030. 2009 –2014
  • Principal Investigator:  “Field Based Oral HIV Testing and Linkage to Government Care in a High HIV Prevalent Region of India”.  MSM Initiative Community Award #107704-47-HAMM. amfAR October 2009
  • Vanguard Leadership Academy graduated February 2012
  • Award of Recognition for Outstanding Leadership 2009: Resurrection Westlake Hospital
  • Golden Apple, 2008: Resurrection Westlake Residency Program
  • Distinguished Physician Award: 2007
  • Indian American Medical Association, Illinois
  • Most Distinguished Physician Award: 2005
  • Osmania University Medical Alumni Association of America
  • Golden Apple, 2003: Resurrection Westlake Residency Program
  • Bronze Apple, 1996: Loyola University Medical Center, Department of Medicine
  • Bronze Apple, 1995: Loyola University Medical Center, Department of Medicine
  • Silver Apple, 1994: Loyola University Medical Center, Department of Medicine
  • Golden Apple, 1992: Grant Hospital of Chicago
  • Outstanding Resident, 1985-1986: Grant Hospital of Chicago
  • Intern of the Year, 1983-1984: Grant Hospital of Chicago
  • Literary Secretary, 1978-1979: Gandhi Medical College
  • V. Yeldandi. Scientific and Technical Education in India Students' Point of View. Asclepiads 1979. (Yearly magazine of Gandhi Medical College)
  • V. Yeldandi, R. Strodtman, and J. R. Lentino. In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 22 (6): 873-880, 1988
  •  A.V. Yeldandi, V. Yeldandi, S. Kumar, Murthy, CV, X. D. Wang, K. Alvares, M. S. Rao, and J. K. Reddy. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene 109 (2): 281-284, 1991
  • A.V. Yeldandi and V. Yeldandi. Molecular Evolution of the Urate Oxidase-Encoding Gene and its Functional Significance. In: Peroxisome Proliferation (Gibson GG and Lake B, Editors)
  • F. Laghi, V. Yeldandi, M. McCabe, and E. R. Garrity, Jr. Common infections complicating lung transplantation. New Jersey Medicine 90 (4): 317-319, 1993
  • V. Yeldandi, F. Laghi, M. A. McCabe, R. Larson, P. O'Keefe, A. Husain, A. Montoya, and E. R. Garrity, Jr. Aspergillus and lung transplantation. Journal of Heart & Lung Transplantation 14 (5): 883-890, 1995
  • N. S. Lurain, H. C. Ammons, K. S. Kapell, V. V. Yeldandi, Garrity, ER, and J. P. O'Keefe. Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. Transplantation 62 (4): 497-502, 1996
  • A.N. Husain, M. T. Siddiqui, V. B. Reddy, V. Yeldandi, A. Montoya, and E. R. Garrity. Postmortem findings in lung transplant recipients. Modern Pathology 9 (7): 752-761, 1996
  • T. J. Walsh, V. Yeldandi, M. McEvoy, C. Gonzalez, S. Chanock, A. Freifeld, N. I. Seibel, P. O. Whitcomb, P. Jarosinski, G. Boswell, I. Bekersky, A. Alak, D. Buell, J. Barret, and W. Wilson. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrobial Agents & Chemotherapy 42 (9): 2391-2398, 1998
  • G. M. Mullen, M. A. Silver, K. Malinowska, C. E. Lawless, R. C. Lichtenberg, Barath, PC, P. J. O'Keefe, J. A. Robinson, and V. Yeldandi. Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients. Transplantation Proceedings 30 (8): 4110-4112, 1998
  • V. A. Lonchyna, J. M. Arcidi, Jr., E. R. Garrity, Jr., K. Simpson, C. Alex, V. Yeldandi, and M. Bokhos. Refractory post-transplant airway strictures: successful management with wire stents. European Journal of Cardio-Thoracic Surgery 15 (6): 842-849, 1999
  • M. C. Ciesla, P. L. Kammeyer, V. Yeldandi, G. J. Petruzzelli and S. L. Yong. Identification of The Asexual State of Rhizopus Species on Histologic Tissue Sections in a Patient With Rhinocerebral Mucormycosis. Archives of Pathology & Laboratory Medicine 124 (6): 883-887, 2000
  • P. J. Cagnoni, T. J. Walsh, M. M. Prendergast, D. Bodensteiner, S. Hiemenz, R.N. Greenberg, C. A. Arndt, M. Schuster, N. Seibel, V. Yeldandi, K.B Tong. Pharmacoeconomic Analysis of Liposomal Amphotericin B versus Conventional Amphotericin B in the Empirical Treatment of Persistently Febrile Neutropenic Patients. Journal of Clinical Oncology 18 (12): 2476-2483, 2000
  • S. M. Bhorade, C. Sandesara, E. R. Garrity, W. T. Vigneswaran, L. Norwick, S. Alkan, A. N. Husain, M. A. McCabe, and V. Yeldandi “ Quantification of Cytomegalovirus (CMV) Viral Load by The Hybrid Capture Assay Allows for Early Detection of CMV Disease in Lung Transplant Recipients”. Journal of Heart & Lung Transplantation 20(9): 928-34, 2001
  • N.S. Lurain, S. M. Bhorade, K. J. Pursell, R. K. Avery, V.V. Yeldandi, C. M. Isada, E. S. Robert, D. J. Kohn, M. Q. Arens, E. R. Garrity, A. J. Taege, M. G. Mullen, K. M. Todd, J. W. Bremer, and B.Yen-Lieberman “Analysis and Characterization of Antiviral Drug-Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients” Journal of Infectious Diseases. 186:760-8, 2002
  • S.M. Steinberg, R.C. Venuto, C.K. Kuruvila, D.O. Taylor, M.S. Anil Kumar, J.R. Groothuis, J. Ryan, R. Greco, V. Yeldandi, T. Ashraf, T. Boodhoo. Prefer Study Group. Randomized, open-label preference study of two cyclosporine capsule formulations (usp modified) in stable solid-organ transplant recipients. Clinical Therapeutics. 2003;25:2037-52
  • Schneider, J. A., Saluja, G. S., Oruganti, G., Dass, S., Tolentino, J., Laumann, E. O., Yeldandi, V.and Pitrak, D. (2007) 'HIV infection dynamics in rural Andhra Pradesh south India: A sexual-network analysis exploratory study', AIDS Care. 2007; 19(9): 1171-1176
  • Schneider JA, Dude A, Dinaker M, Kumar V, Laumann EO, Holloway-Beth A, Oruganti G, Saluja GS, Chundi V, Yeldandi V, Mayer KH. General Hygiene, Sexual Risk Behavior and HIV Prevalence in Truck Drivers from Andhra Pradesh, South India: Implications for Prevention Interventions. International Journal of STD & AIDS. 2009; 20(1): 39-45
  • Sudha Sivaram, Gurcharan Singh Saluja, Manik Das, P. Sudhakar Reddy and Vijay Yeldandi 
  • “Reasons for Seeking HIV-test: Evidence from a Private Hospital in Rural Andhra Pradesh, India” J HEALTH POPUL NUTR 2008 Dec;26(4):431-441
  • Dupont BF, Lortholary O, Zeichner LO, Stucker F and Yeldandi V “Treatment of candidemia and invasive Candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Critical Care 2009, 13: R159
  • Schneider JA, Dandona R, Pasupneti S, Lakshmi V, Liao C, Yeldandi V, Mayer K. “Initial commitment to pre-exposure prophylaxis and circumcision for HIV prevention amongst Indian truck drivers” . PLoS ONE. 2010 Jul 30;5(7):e11922
  • Schneider JA, Michaels S, Gandham SR, McFadden R, Liao C, Yeldandi VV, Oruganti G.A protective effect of circumcision among receptive male sex partners of Indian men who have sex with men. AIDS Behav. 2012 Feb;16(2):350-9. PMID: 21681562
  •  Snyder H, Yeldandi VV, Prem Kumar G, Liao C, Lakshmi V, Gandham SR, Muppudi U, Oruganti G, Schneider JA. Field-based video pre-test counseling, oral testing, and telephonic post-test counseling: implementation of an HIV field testing package among high-risk Indian men.AIDS Educ Prev. 2012 Aug;24(4):309-26
  • Ganesh Oruganti, Manjunath Dinaker, Kattula Sri Rama Surya Tez, Jammy Guru Rajesh, 
  • Yeldandi V. Vijay, P.S.Reddy. High Sero-prevalence of Dengue IgG antibodies among healthy individuals in Andhra Pradesh, India. Accepted for publication: Indian Journal of Public Health Research & Development. January-March 2014
  • Fellow American College of Physicians
  • Fellow American College of Chest Physicians
  • Member Infectious Disease Society of America
  • Member Society for Healthcare Epidemiology of America
  • Member Association for Professionals in Infection Control and Epidemiology
  • Chicago Area Infectious Disease Society
  • American Association of Physicians of Indian Origin
  • Indian American Medical Association (Illinois)
  • HIV Medicine Association
  • International AIDS Society
  • American Society of Transplantation